| Literature DB >> 11317267 |
G Quaglio1, F Lugoboni, S Vento, A Lechi, A Accordini, C Bossi, M Faccini, V Mecenero, A Pani, M Pantalena, M Residori, P Mezzelani.
Abstract
In a study of 497 injection drug users who had isolated presence of antibody to hepatitis B core antigen (anti-HBc) at the time of enrollment, 404 (81%) retained this condition after a mean of 49 months of follow-up, during which time no new hepatitis B surface antigen marker was detected. These findings support the hypothesis that patients with isolated presence of anti-HBc have strong resistance to reinfection and do not need vaccination.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11317267 DOI: 10.1086/320162
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 9.079